• Dr. Lebensburger is Director, Pediatric Hematology Section in the Division of Pediatric Hematology Oncology. He has expertise in sickle cell disease and hemoglobinopathies, red cell disorders, ITP, bleeding disorders, blood clotting disorders, bone marrow failure syndromes, and general hematology.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 Hyperfiltration during early childhood precedes albuminuria in pediatric sickle cell nephropathyAmerican Journal of Hematology.  94:417-423. 2019
    2019 Hypomorphic caspase activation and recruitment domain 11 (CARD11) mutations associated with diverse immunologic phenotypes with or without atopic diseaseJournal of Allergy and Clinical Immunology.  143:1482-1495. 2019
    2019 Hydroxyurea prevents onset and progression of albuminuria in children with sickle cell anemiaAmerican Journal of Hematology.  94:E27-E29. 2019
    2018 Impact of early analgesia on hospitalization outcomes for sickle cell pain crisisMedical and Pediatric Oncology.  65. 2018
    2018 Red blood cell transfusion therapy for sickle cell patients with frequent painful eventsMedical and Pediatric Oncology.  65. 2018
    2018 Outcomes of febrile events in pediatric patients with sickle cell anemiaMedical and Pediatric Oncology.  65. 2018
    2018 Sickle Cell Clinical Research and Intervention Program (SCCRIP): A lifespan cohort study for sickle cell disease progression from the pediatric stage into adulthoodMedical and Pediatric Oncology.  65. 2018
    2018 Acute kidney injury during parvovirus B19-induced transient aplastic crisis in sickle cell diseaseAmerican Journal of Hematology.  93:E198-E200. 2018
    2018 Management of severe chronic pain with methadone in pediatric patients with sickle cell diseaseMedical and Pediatric Oncology.  65. 2018
    2018 Outcomes in mild to moderate isolated thrombocytopeniaPediatrics.  142. 2018
    2018 Hydroxycarbamide for patients with silent cerebral infarcts: outcomes and patient preferenceBritish Journal of Haematology.  181:145-148. 2018
    2017 Evaluating risk factors for chronic kidney disease in pediatric patients with sickle cell anemiaPediatric Nephrology.  32:1565-1573. 2017
    2017 Acute kidney injury during a pediatric sickle cell vaso-occlusive pain crisisPediatric Nephrology.  32:1451-1456. 2017
    2017 Publication outcomes of abstracts from the American Society of Hematology Annual MeetingAmerican Journal of Hematology.  92:E81-E83. 2017
    2017 Cranial epidural hematomas: A case series and literature review of this rare complication associated with sickle cell diseaseMedical and Pediatric Oncology.  64. 2017
    2017 Severe anemia early in life as a risk factor for sickle-cell kidney diseaseBlood.  129:385-387. 2017
    2017 Elective cholecystectomy reduces morbidity of cholelithiasis in pediatric sickle cell diseaseMedical and Pediatric Oncology.  64:113-120. 2017
    2016 Absorbance and redox based approaches for measuring free heme and free hemoglobin in biological matricesRedox Biology.  9:167-177. 2016
    2016 Prevalence of acute kidney injury during pediatric admissions for acute chest syndromePediatric Nephrology.  31:1363-1368. 2016
    2016 Maintaining high level of care at satellite sickle cell clinicsJournal of Health Care for the Poor and Underserved.  27:280-292. 2016
    2015 Hydroxyurea decreases hospitalizations in pediatric patients with Hb SC and Hb SB+ thalassemiaJournal of Blood Medicine.  6:285-290. 2015
    2015 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 studyMedical and Pediatric Oncology.  62:1427-1436. 2015
    2015 Encephaloduroarteriosynangiosis and encephalomyoarteriosynangiosis for treatment of moyamoya syndrome in pediatric patients with sickle cell diseaseJournal of Neurosurgery: Pediatrics.  16:64-73. 2015
    2015 Exploring Adult Care Experiences and Barriers to Transition in Adult Patients with Sickle Cell Disease.International journal of hematology & therapy.  1. 2015
    2015 Patient-centered approach to designing sickle cell transition educationJournal of Pediatric Hematology/Oncology.  37:43-47. 2015
    2015 Systematic review of interventional sickle cell trials registered in ClinicalTrials.govClinical Trials.  12:575-583. 2015
    2015 Understanding and improving health education among first-time parents of infants with sickle cell anemia in alabama: A mixed methods approachJournal of Pediatric Hematology/Oncology.  37:35-42. 2015
    2014 Understanding and improving health education among first-time parents of infants with sickle cell anemia in Alabama: A mixed methods approachJournal of Pediatric Hematology/Oncology2014
    2014 Ferritin and LIC: Predicting liver injury in children with sickle cellJournal of Pediatric Gastroenterology and Nutrition.  58:387-390. 2014
    2014 Social skills and executive function among youth with sickle cell disease: A preliminary investigationJournal of Pediatric Psychology.  39:493-500. 2014
    2013 Exploring barriers and facilitators to clinical trial enrollment in the context of sickle cell anemia and hydroxyureaMedical and Pediatric Oncology.  60:1333-1337. 2013
    2013 Hydroxyurea treatment of children with hemoglobin SC diseaseMedical and Pediatric Oncology.  60:323-325. 2013
    2012 Influence of severity of anemia on clinical findings in infants with sickle cell anemia: Analyses from the BABY HUG studyMedical and Pediatric Oncology.  59:675-678. 2012
    2012 Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectinBlood.  119:1915-1921. 2012
    2012 Barriers in transition from pediatrics to adult medicine in sickle cell anemia.Journal of Blood Medicine.  3:105-112. 2012
    2011 Laboratory and clinical correlates for magnetic resonance imaging (MRI) abnormalities in pediatric sickle cell anemiaJournal of Child Neurology.  26:1260-1264. 2011
    2011 Protective role of hemoglobin and fetal hemoglobin in early kidney disease for children with sickle cell anemiaAmerican Journal of Hematology.  86:430-432. 2011
    2011 What is the evidence for using hydroxyurea for secondary stroke prevention?Hematology online (ASH).  2011:440-442. 2011

    Research Overview

  • Dr. Lebensburger has received funding from the National Institutes of Health, American Society of Hematology, Patient Centered Outcomes Research Institute to study sickle cell organ complications, transition of care, and patient education. He is also an investigator for the ITP Consortium of North America.
  • Teaching Overview

  • Dr. Lebensburger teaches a wide array of courses in Hematology to Medical students, Pediatric residents, and pediatric Hematology Oncology Fellows.
    Dr. Lebensburger also serves as faculty at the American Society of Hematology Clinical Research Training Institute where he mentors young leaders in the field throughout the country.
  • Education And Training

  • Doctor of Osteopathy in Osteopathic Medicine / Osteopathy, Nova Southeastern University 2003
  • Arnold Palmer Children's Hospital, Internship 2004
  • Arnold Palmer Children's Hospital, Residency 2006
  • St. Jude Children's Research Hospital, Postdoctoral Fellowship 2009
  • Full Name

  • Jeffrey Lebensburger